Literature DB >> 25956732

Wogonin inhibits LPS-induced vascular permeability via suppressing MLCK/MLC pathway.

Yujie Huang1, Xuwei Luo1, Xiaorui Li1, Xiuming Song2, Libin Wei1, Zhiyu Li3, Qidong You4, Qinglong Guo5, Na Lu1.   

Abstract

Wogonin, a naturally occurring monoflavonoid extracted from the root of Scutellaria baicalensis Georgi, has been shown to have anti-inflammatory and anti-tumor activities and inhibits oxidant stress-induced vascular permeability. However, the influence of wogonin on vascular hyperpermeability induced by overabounded inflammatory factors often appears in inflammatory diseases and tumor is not well known. In this study, we evaluate the effects of wogonin on LPS induced vascular permeability in human umbilical vein endothelial cells (HUVECs) and investigate the underlying mechanisms. We find that wogonin suppresses the LPS-stimulated hyperactivity and cytoskeleton remodeling of HUVECs, promotes the expression of junctional proteins including VE-Cadherin, Claudin-5 and ZO-1, as well as inhibits the invasion of MDA-MB-231 across EC monolayer. Miles vascular permeability assay proves that wogonin can restrain the extravasated Evans in vivo. The mechanism studies reveal that the expressions of TLR4, p-PLC, p-MLCK and p-MLC are decreased by wogonin without changing the total steady state protein levels of PLC, MLCK and MLC. Moreover, wogonin can also inhibit KCl-activated MLCK/MLC pathway, and further affect vascular permeability. Significantly, compared with wortmannin, the inhibitor of MLCK/MLC pathway, wogonin exhibits similar inhibition effects on the expression of p-MLCK, p-MLC and LPS-induced vascular hyperpermeability. Taken together, wogonin can inhibit LPS-induced vascular permeability by suppressing the MLCK/MLC pathway, suggesting a therapeutic potential for the diseases associated with the development of both inflammatory and tumor.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lipopolysaccharide (LPS); MLCK/MLC; Vascular permeability; Wogonin; Wogonin (PubChem CID: 5281703); Wortmannin (PubChem CID: 312145)

Mesh:

Substances:

Year:  2015        PMID: 25956732     DOI: 10.1016/j.vph.2015.04.012

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  4 in total

1.  Key Molecular Mechanisms of Chaiqinchengqi Decoction in Alleviating the Pulmonary Albumin Leakage Caused by Endotoxemia in Severe Acute Pancreatitis Rats.

Authors:  Wei Wu; Ruijie Luo; Ziqi Lin; Qing Xia; Ping Xue
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-19       Impact factor: 2.629

Review 2.  Myosin Light Chain Kinase: A Potential Target for Treatment of Inflammatory Diseases.

Authors:  Yongjian Xiong; Chenou Wang; Liqiang Shi; Liang Wang; Zijuan Zhou; Dapeng Chen; Jingyu Wang; Huishu Guo
Journal:  Front Pharmacol       Date:  2017-05-23       Impact factor: 5.810

3.  ML-7 attenuates airway inflammation and remodeling via inhibiting the secretion of Th2 cytokines in mice model of asthma.

Authors:  Chuanjun Huang; Zewen Zhang; Liuxin Wang; Ju Liu; Xiaodan Gong; Caiqing Zhang
Journal:  Mol Med Rep       Date:  2018-03-06       Impact factor: 2.952

Review 4.  Differential Regulation of LPS-Mediated VE-Cadherin Disruption in Human Endothelial Cells and the Underlying Signaling Pathways: A Mini Review.

Authors:  Yee Han Chan; Hanis Hazeera Harith; Daud Ahmad Israf; Chau Ling Tham
Journal:  Front Cell Dev Biol       Date:  2020-01-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.